The Role of Macrophages in Cancer Development and Therapy

Cendrowicz, Ewa; Sas, Zuzanna; Bremer, Edwin; Rygiel, Tomasz P.

doi:10.3390/cancers13081946

Cited by 332Immune cells in cancerPhagocytosis and Immune RegulationCancer, Stress, Anesthesia, and Immune Response

The Role of Macrophages in Cancer Development and Therapy

Open access

Cendrowicz, Ewa, Sas, Zuzanna, Bremer, Edwin, Rygiel, Tomasz P.·2021·Cancers

DOI 10.3390/cancers13081946PMC PMC8073377

Open this paper in CoChat — free account Open PDF

Abstract

Macrophages are critical mediators of tissue homeostasis and influence various aspects of immunity. Tumor-associated macrophages are one of the main cellular components of the tumor microenvironment. Depending on their activation status, macrophages can exert a dual influence on tumorigenesis by either antagonizing the cytotoxic activity of immune cells or, less frequently, by enhancing antitumor responses. In most situations, TAMs suppress T cell recruitment and function or regulate other aspects of tumor immunity. The importance of TAMs targeting in cancer therapy is derived from the strong association between the high infiltration of TAMs in the tumor tissue with poor patient prognosis. Several macrophage-targeting approaches in anticancer therapy are developed, including TAM depletion, inhibition of new TAM differentiation, or re-education of TAM activation for cancer cell phagocytosis. In this review, we will describe the role of TAMs in tumor development, including such aspects as protumorigenic inflammation, immune suppression, neoangiogenesis, and enhancement of tissue invasion and distant metastasis. Furthermore, we will discuss therapeutic approaches that aim to deplete TAMs or, on the contrary, re-educate TAMs for cancer cell phagocytosis and antitumor immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/cancers13081946

Cites

188 of 188 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Tumor-derived cues generally favor M2 polarization of macrophages, resulting in secretion of cytokines such as IL-4, IL-6, IL-1β, and TNFα that support tumor growth by enhancing proliferation, remodeling ECM, and inhibiting effector T-cell responses.
“Tumor-derived cues generally favor M2 polarization, resulting in the secretion of cytokines such as IL-4, IL-6, IL-1β, and TNFα. These cytokines support tumor growth by enhancing cellular proliferation, remodeling the ECM, and inhibiting effector T-cell responses. Thus, TAMs serve as both immunological suppressors and facilitators of malignant progression [70,71].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [70]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Inflammation and cancer
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111 · see citing works
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · see citing works
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · see citing works
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337 · see citing works
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777 · see citing works
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · see citing works
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · see citing works
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806 · see citing works
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · see citing works
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376 · see citing works
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · see citing works
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation
Italiani, P., & Boraschi, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00514 · Cited by 2,067 · see citing works
Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated Macrophages
Orecchioni, M., Ghosheh, Y., Pramod, A. B., & Ley, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01084 · Cited by 2,063 · see citing works
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 2,040 · see citing works
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847 · cited 1× · see citing works
“The angiopoietin-1 released from pericytes binds to Tie-2 receptor on ECs, leading to tightening of ECs’ cell-cell junctions and stabilization of newly formed vessels (Figure 2) [41].”
Background
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784 · cited 1× · see citing works
“Tumors are dynamic and heterogeneous tissues that depend on the microenvironment, with a complex relationship between cancer cells and infiltrating immune cells [67,68].”
Background
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765 · see citing works
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P. D., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R. K., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,667 · see citing works
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608 · see citing works
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586 · see citing works
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578 · see citing works
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495 · see citing works
Angiogenesis in cancer
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,467 · see citing works
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
Lin, Y., Xu, J., & Lan, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0760-3 · Cited by 1,398 · see citing works
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,391 · see citing works
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311 · see citing works
HIF transcription factors, inflammation, and immunity
Palazon, A., Goldrath, A. W., Nizet, V., & Johnson, R. S. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.008 · Cited by 1,195 · see citing works
A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors
Wyckoff, J. B., Wang, W., Lin, E. Y., Wang, Y., Pixley, F. J., Stanley, E. R., Graf, T., Pollard, J. W., Segall, J. E., & Condeelis, J. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1449 · Cited by 1,189 · see citing works
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,118 · see citing works
Role of Matrix Metalloproteinases in Angiogenesis and Cancer
Quintero-Fabián, S., Arreola, R., Becerril‐Villanueva, E., Torres‐Romero, J. C., Arana‐Argáez, V. E., Lara‐Riegos, J., Ramírez-Camacho, M. A., & Álvarez-Sánchez, M. E. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01370 · Cited by 1,042 · see citing works
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,029 · see citing works
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926 · see citing works
Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y., & Weissman, I. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0183-z · Cited by 914 · see citing works
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 863 · see citing works
The CC chemokine CCL20 and its receptor CCR6
Schutyser, E., Struyf, S., & Damme, J. V. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00049-2 · Cited by 777 · see citing works
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 739 · see citing works
A Distinct Macrophage Population Mediates Metastatic Breast Cancer Cell Extravasation, Establishment and Growth
Qian, B., Deng, Y., Im, J. H., Muschel, R. J., Zou, Y., Li, J., Lang, R. A., & Pollard, J. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006562 · Cited by 664 · see citing works
How do Regulatory T Cells Work?
Corthay, A. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02308.x · Cited by 650 · see citing works
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Thomas, S. J., Snowden, J. A., Zeidler, M. P., & Danson, S. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.233 · Cited by 639 · see citing works
Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis
Riabov, V., Gudima, A., Wang, N., Mickley, A., Orekhov, A. N., & Kzhyshkowska, J. G. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00075 · Cited by 631 · see citing works
Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs
Chen, Q., Zhang, X. H.-F., & Massagué, J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.025 · Cited by 619 · see citing works
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Georgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609 · see citing works
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Sikic, B. I., Lakhani, N. J., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D. W., Colevas, A. D., O’Rourke, T. J., Narayanan, S., Papadopoulos, K. P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02018 · Cited by 603 · see citing works
EMT and inflammation: inseparable actors of cancer progression
Suarez‐Carmona, M., Lesage, J., Cataldo, D. D., & Gilles, C. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12095 · Cited by 573 · see citing works
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bockorny, B., Semenisty, V., Macarulla, T. M., Borazanci, E. H., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 563 · see citing works
Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice
Jayasingam, S., Citartan, M., Thang, T. H., Zin, A. A. M., Kai, C.-E.-A., & Ch'ng, E. S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01512 · Cited by 554 · see citing works
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544 · see citing works
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
Zhang, F., Parayath, N. N., Ene, C., Stephan, S. B., Koehne, A. L., Coon, M. E., Holland, E. C., & Stephan, M. T. (2019) · Nature Communications · doi:10.1038/s41467-019-11911-5 · Cited by 526 · see citing works
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N., & Muschel, R. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7376 · Cited by 504 · see citing works
Targeting Macrophages in Cancer: From Bench to Bedside
Poh, A. R., & Ernst, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00049 · Cited by 497 · see citing works
Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly
Kim, H. J., Lee, H. J., Kim, H., Cho, S. W., & Kim, J.-S. (2009) · Genome Research · doi:10.1101/gr.089417.108 · Cited by 466 · see citing works
Role of the NFκB-signaling pathway in cancer
Xia, L., Tan, S., Zhou, Y., Lin, J., Wang, H., Oyang, L., Tian, Y., Liu, L., Su, M., Wang, H., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161109 · Cited by 461 · see citing works
Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450 · see citing works
CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis
Yang, H., Zhang, Q., Xu, M., Wang, L., Chen, X., Feng, Y., Li, Y., Zhang, X., Cui, W., & Jia, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01165-x · Cited by 449 · see citing works
Localized Interleukin-12 for Cancer Immunotherapy
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575597 · Cited by 433 · see citing works
Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner
Wanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420 · see citing works
The CCL5/CCR5 Axis in Cancer Progression
Aldinucci, D., Borghese, C., & Casagrande, N. (2020) · Cancers · doi:10.3390/cancers12071765 · Cited by 413 · see citing works
Arginine and Immunity
Popovič, P., Zeh, H. J., & Ochoa, J. B. (2007) · Journal of Nutrition · doi:10.1093/jn/137.6.1681s · Cited by 406 · see citing works
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 374 · see citing works
Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha.
Torisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., NAKAYAMA, J., Nishioka, Y., Sone, S., & Kuwano, M. (2000) · PubMed · Cited by 363 · see citing works
Crosstalk between cancer and immune cells: Role of tumor‐associated macrophages in the tumor microenvironment
Wang, J., Li, D., Cang, H., & Guo, B. (2019) · Cancer Medicine · doi:10.1002/cam4.2327 · Cited by 353 · see citing works
Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo
Loberg, R. D., Chi, Y., Craig, M., Day, L. L., Sargent, E., Neeley, C. K., Wojno, K. J., Snyder, L. A., Li, Y., & Pienta, K. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1286 · Cited by 333 · see citing works
Interferon‐γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages
Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E. C., Ponsoda, S., Delneste, Y., Hebbar, M., & Jeannin, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24401 · Cited by 328 · see citing works
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
Flores‐Toro, J., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., Singh, R., Schall, T. J., Datta, M., Jain, R. K., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910856117 · Cited by 326 · see citing works
Interaction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322 · see citing works
TGF-β: Guardian of T Cell Function
Oh, S. A., & Li, M. O. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301843 · Cited by 320 · see citing works
Macrophage Metabolism As Therapeutic Target for Cancer, Atherosclerosis, and Obesity
Geeraerts, X., Bolli, E., Fendt, S., & Ginderachter, J. A. V. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00289 · Cited by 315 · see citing works
Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma
Czystowska, M., Sosnowska, A., Nowis, D., Ramji, K., Szajnik, M. E., Chlebowska, J., Wolińska, E., Gaj, P., Grażul, M., Pilch, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10979-3 · Cited by 315 · see citing works
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30532-5 · Cited by 307 · see citing works
Molecular Repolarisation of Tumour-Associated Macrophages
van Dalen, F. J., van Stevendaal, M. H. M. E., Fennemann, F. L., Verdoes, M., & Ilina, O. (2018) · Molecules · doi:10.3390/molecules24010009 · Cited by 304 · see citing works
Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas.
Nishie, A., Ono, M., Shono, T., Fukushi, J., Otsubo, M., Onoue, H., Ito, Y., Inamura, T., 清信, 池., Fukui, M., et al. (1999) · PubMed · Cited by 301 · see citing works
IL-1 Family Members in Cancer; Two Sides to Every Story
Baker, K. J., Houston, A. M., & Brint, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01197 · Cited by 285 · see citing works
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors
Bonde, A.-K., Tischler, V., Kumar, S., Soltermann, A., & Schwendener, R. A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-35 · Cited by 284 · see citing works
Macrophages as Key Drivers of Cancer Progression and Metastasis
Nielsen, S. R., & Schmid, M. C. (2017) · Mediators of Inflammation · doi:10.1155/2017/9624760 · Cited by 281 · see citing works
Macrophage Infiltration and Heme Oxygenase-1 Expression Correlate with Angiogenesis in Human Gliomas
西江, 昭. (2001) · Medical Entomology and Zoology · doi:10.11501/3181003 · Cited by 278 · see citing works
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Anfray, C., Ummarino, A., Andón, F. T., & Allavena, P. (2019) · Cells · doi:10.3390/cells9010046 · Cited by 275 · see citing works
Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFα and IL-1α
Torisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., NAKAYAMA, J., Nishioka, Y., Sone, S., & Kuwano, M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000115)85:2%3c182::aid-ijc6%3e3.0.co;2-m · Cited by 254 · see citing works
Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy
Zheng, X., Turkowski, K., Mora, J., Brüne, B., Seeger, W., Weigert, A., & Savai, R. (2017) · OncoTarget · doi:10.18632/oncotarget.17061 · Cited by 250 · see citing works
Pexidartinib: First Approval
Lamb, Y. N. (2019) · Drugs · doi:10.1007/s40265-019-01210-0 · Cited by 243 · see citing works
Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages
Müller, E., CHRISTOPOULOS, P. F., Halder, S., Lunde, A., Beraki, K., Speth, M. T., Øynebråten, I., & Corthay, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01383 · Cited by 241 · see citing works
Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas
Yan, D., Kowal, J., Akkari, L., Schuhmacher, A. J., Huse, J. T., West, B. L., & Joyce, J. A. (2017) · Oncogene · doi:10.1038/onc.2017.261 · Cited by 233 · see citing works
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
Jiao, X., Nawab, O., Patel, T. A., Kossenkov, A. V., Halama, N., Jaeger, D., & Pestell, R. G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1167 · Cited by 232 · see citing works
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
Michaelis, K. A., Norgard, M. A., Zhu, X., Levasseur, P. R., Sivagnanam, S., Liudahl, S. M., Burfeind, K. G., Olson, B. G., Pelz, K. R., Ramos, D. M. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12657-w · Cited by 231 · see citing works
Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function
Fleur, L. L., Botling, J., He, F., Pelicano, C., Zhou, C., He, C., Palano, G., Mezheyeuski, A., Micke, P., Ravetch, J. V., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1885 · Cited by 226 · see citing works
The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy
Ge, Z., & Ding, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590941 · Cited by 224 · see citing works
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
Rook, A. H., Gelfand, J. M., Wysocka, M., Troxel, A. B., Benoit, B. M., Surber, C., Elenitsas, R., Buchanan, M., Leahy, D. S., Watanabe, R., et al. (2015) · Blood · doi:10.1182/blood-2015-02-630335 · Cited by 223 · see citing works
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
D’Incalci, M., Badri, N., Galmarini, C. M., & Allavena, P. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.149 · Cited by 219 · see citing works
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
Braña, I., Calles, A., LoRusso, P. M., Yee, L., Puchalski, T. A., Seetharam, S., Zhong, B., de Boer, C. J., Tabernero, J. M., & Calvo, E. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0320-2 · Cited by 218 · see citing works
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
Gomez-Roca, C., Italiano, A., Tourneau, C. L., Cassier, P. A., Toulmonde, M., D’Angelo, S. P., Campone, M., WEBER, K. L., Loirat, D., Cannarile, M. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz163 · Cited by 215 · see citing works
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Papadopoulos, K. P., Gluck, L., Martin, L. P., Olszanski, A. J., Tolcher, A. W., Ngarmchamnanrith, G., Rasmussen, E., Amore, B. M., Nagorsen, D., Hill, J. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3261 · Cited by 210 · see citing works
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Ansell, S. M., Maris, M. B., Lesokhin, A. M., Chen, R. W., Flinn, I. W., Sawas, A., Minden, M. D., Villa, D. R., Percival, M. M., Advani, A. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3706 · Cited by 204 · see citing works
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00830-3 · Cited by 199 · see citing works
CAR T cell therapy: A new era for cancer treatment (Review)
Mohanty, R., Chowdhury, C. R., Arega, S., Sen, P., Ganguly, P., & Ganguly, N. (2019) · Oncology Reports · doi:10.3892/or.2019.7335 · Cited by 192 · see citing works
Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors
Argyle, D. J., & Kitamura, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02629 · Cited by 190 · see citing works
Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer
Lin, W., Xu, D., Austin, C. D., Caplazi, P., Senger, K., Sun, Y., Jeet, S., Young, J., Delarosa, D., Suto, E., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02019 · Cited by 187 · see citing works
MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis
Cook, R. S., Jacobsen, K. M., Wofford, A., DeRyckere, D., Stanford, J. C., Prieto, A. L., Redente, E. F., Sandahl, M. A., Hunter, D. M., Strunk, K. E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67655 · Cited by 186 · see citing works
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
Tu, M. M., Abdel-Hafiz, H. A., Jones, R. T., Jean, A., Hoff, K. J., Duex, J. E., Chauca-Diaz, A., Costello, J. C., Dancik, G. M., Tamburini, B. A. J., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01441-y · Cited by 179 · see citing works
Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype
Beider, K., Bitner, H., Leiba, M., Gutwein, O., Koren‐Michowitz, M., Ostrovsky, O., Abraham, M., Wald, H., Galun, E., Peled, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2207 · Cited by 171 · see citing works
Combined Effects of Pericytes in the Tumor Microenvironment
Ribeiro, A. L., & Okamoto, O. K. (2015) · Stem Cells International · doi:10.1155/2015/868475 · Cited by 168 · see citing works
Role of CD47 in Hematological Malignancies
Eladl, E., Tremblay‐LeMay, R., Rastgoo, N., Musani, R., Chen, W.-M., Liu, A., & Chang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00930-1 · Cited by 161 · see citing works
Immune suppression and reversal of the suppressive tumor microenvironment
Shimizu, K., Iyoda, T., Okada, M., Yamasaki, S., & Fujii, S. (2018) · International Immunology · doi:10.1093/intimm/dxy042 · Cited by 159 · see citing works
TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression
Vidyarthi, A., Khan, N., Agnihotri, T., Negi, S., Das, D. K., Aqdas, M., Chatterjee, D., Colegio, O. R., Tewari, M. K., & Agrewala, J. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01650 · Cited by 157 · see citing works
The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis
Muñoz-García, J., Cochonneau, D., Télétchéa, S., Moranton, E., Lanoé, D., Brion, R., Lézot, F., Heymann, M., & Heymann, D. (2020) · Theranostics · doi:10.7150/thno.50683 · Cited by 155 · see citing works
An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains.
Campbell, I., Freemont, P. S., Foulkes, W. D., & Trowsdale, J. (1992) · PubMed · Cited by 140 · see citing works
High-Infiltration of Tumor-Associated Macrophages Predicts Unfavorable Clinical Outcome for Node-Negative Breast Cancer
Zhang, Y., Cheng, S., Zhang, M., Zhen, L., Pang, D., Zhang, Q., & Li, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076147 · Cited by 139 · see citing works
CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial–mesenchymal transition
Cheng, X., Li, Y., Tan, J. Y., Sun, B., Xiao, Y., Fang, X.-B., Zhang, X., Li, Q., Dong, J., Li, M., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.008 · Cited by 138 · see citing works
Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy
Figueiredo, P., Lepland, A., Scodeller, P., Fontana, F., Torrieri, G., Tiboni, M., Shahbazi, M., Casettari, L., Kostiainen, M. A., Hirvonen, J. J., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.09.038 · Cited by 137 · see citing works
F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner
Yumimoto, K., Akiyoshi, S., Ueo, H., Sagara, Y., Onoyama, I., Ueo, H., Ohno, S., Mori, M., Mimori, K., & Nakayama, K. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78782 · Cited by 134 · see citing works
Prognostic Significance of Tumor-Associated Macrophage Content in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
Kumar, A., Knops, A. M., Swendseid, B. P., Martinez-Outschoom, U., Harshyne, L. A., Philp, N. J., Rodeck, U., Luginbuhl, A., Cognetti, D. M., Johnson, J. M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00656 · Cited by 134 · see citing works
Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma
Fu, X.-T., Song, K., Zhou, J., Shi, Y.-H., Liu, W.-R., Shi, G., Gao, Q., Wang, X.-Y., Ding, Z.-B., & Fan, J. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0771-8 · Cited by 133 · see citing works
CD40 Ligation Activates Murine Macrophages via an IFN-γ-Dependent Mechanism Resulting in Tumor Cell Destruction In Vitro
Buhtoiarov, I. N., Lum, H. D., Berke, G., Paulnock, D. M., Sondel, P. M., & Rakhmilevich, A. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6013 · Cited by 125 · see citing works
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Razak, A. R., Cleary, J. M., Moreno, V., Boyer, M. J., Calvo, E., Edenfield, W. J., Tie, J., Harvey, R. D., Rutten, A., Shah, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001006 · Cited by 124 · see citing works
Tumor‑infiltrating M2�macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer
Xue, Y., Tong, L., Liu, F., Liu, A., Zeng, S., Xiong, Q., Yang, Z., He, X., Sun, Y., & Xu, C. (2019) · Oncology Reports · doi:10.3892/or.2019.7196 · Cited by 123 · see citing works
Overview of CD24 as a new molecular marker in ovarian cancer
Tarhriz, V., Bandehpour, M., Dastmalchi, S., Ouladsahebmadarek, E., Zarredar, H., & Eyvazi, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27581 · Cited by 122 · see citing works
Macrophages‐Triggered Sequential Remodeling of Endothelium‐Interstitial Matrix to Form Pre‐Metastatic Niche in Microfluidic Tumor Microenvironment
Kim, H., Chung, H., Kim, J., Choi, D., Shin, Y., Kang, Y. G., Kim, B., Seo, S., Chung, S. H., & Seok, S. H. (2019) · Advanced Science · doi:10.1002/advs.201900195 · Cited by 116 · see citing works
Synergy between Coproduced CC and CXC Chemokines in Monocyte Chemotaxis through Receptor-Mediated Events
Gouwy, M., Struyf, S., Noppen, S., Schutyser, E., Springael, J., Parmentier, M., Proost, P., & Damme, J. V. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.045146 · Cited by 115 · see citing works
Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
Jalil, A. R., Andrechak, J. C., & Discher, D. E. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa006 · Cited by 115 · see citing works
Interaction of CTLA‐4 (CD152) with CD80 or CD86 inhibits human T‐cell activation
Vandenborre, K., Gool, S. W. V., Kasran, A., Ceuppens, J. L., Boogaerts, M. A., & Vandenberghe, P. (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00888.x · Cited by 113 · see citing works
Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes
Li, H., Somiya, M., & Kuroda, S. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120601 · Cited by 107 · see citing works
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
Veltman, J. D., Lambers, M. E. H., van Nimwegen, M., Hendriks, R. W., Hoogsteden, H. C., Hegmans, J. P., & Aerts, J. G. J. V. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605814 · Cited by 104 · see citing works
Targeting PDGF‐mediated recruitment of pericytes blocks vascular mimicry and tumor growth
Thijssen, V. L., Paulis, Y. W. J., Nowak-Sliwinska, P. M., Deumelandt, K., Hosaka, K., Soetekouw, P. M. M. B., Cîmpean, A. M., Raica, M., Pauwels, P., van den Oord, J. J., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5152 · Cited by 103 · see citing works
Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-κB-CCL2 signaling in lung cancer
Zhou, L., Jiang, Y., Liu, X., Li, L., Yang, X., Dong, C., Liu, X., Lin, Y., Yan, L., Yu, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0840-4 · Cited by 103 · see citing works
The activation status of human macrophages presenting antigen determines the efficiency of Th17 responses
Arnold, C. E., Gordon, P. M., Barker, R. N., & Wilson, H. M. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.09.022 · Cited by 98 · see citing works
Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
Sabado, R. L., Pavlick, A. C., Gnjatic, S., Cruz, C. M., Vengco, I., Hasan, F., Spadaccia, M. R., Darvishian, F., Chiriboga, L. A., Holman, R. M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0202 · Cited by 96 · see citing works
Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.
Linehan, D. C., Noel, M. S., Hezel, A. F., Wang‐Gillam, A., Eskens, F. A. L. M., Sleijfer, S., Desar, I. M. E., Erdkamp, F., Wilmink, J. W., Diehl, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.92 · Cited by 93 · see citing works
Expression of scavenger receptor MARCO defines a targetable tumor‐associated macrophage subset in non‐small cell lung cancer
Fleur, L. L., Boura, V. F., Alexeyenko, A., Berglund, A., Pontén, V., Mattsson, J. S. M., Djureinovic, D., Persson, J., Brunnström, H., Isaksson, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31545 · Cited by 93 · see citing works
RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
Cabrales, P. (2019) · Translational Oncology · doi:10.1016/j.tranon.2018.12.001 · Cited by 93 · see citing works
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen
Barone, A. K., Chi, D.-C., Theoret, M. R., Chen, H., He, K., Kufrin, D., Helms, W. S., Subramaniam, S., Zhao, H., Patel, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0898 · Cited by 89 · see citing works
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Brempelis, K. J., Cowan, C. M., Kreuser, S. A., Labadie, K. P., Prieskorn, B. M., Lieberman, N. A. P., Ene, C., Moyes, K. W., Chinn, H. K., DeGolier, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001356 · Cited by 84 · see citing works
Macrophages and tumor angiogenesis
Ribatti, D., Nico, B., Enrico Crivellato, B., & Vacca, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404900 · Cited by 83 · see citing works
Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment
Liguori, M., Buracchi, C., Pasqualini, F., Bergomas, F., Pesce, S., Sironi, M., Grizzi, F., Mantovani, A., Belgiovine, C., & Allavena, P. (2016) · OncoTarget · doi:10.18632/oncotarget.9340 · Cited by 81 · see citing works
Prognostic significance of tumor-associated macrophages: past, present and future
Cortese, N., Carriero, R., Laghi, L., Mantovani, A., & Marchesi, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101408 · Cited by 78 · see citing works
HPV-based cervical cancer screening in a population at high risk for HIV infection
Womack, S. D., Chirenje, Z. M., Gaffikin, L., Blumenthal, P. D., McGrath, J. A., Chipato, T., Ngwalle, S., Munjoma, M. W., & Shah, K. V. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000115)85:2 · Cited by 78 · see citing works
Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer
Ranasinghe, R., & Eri, R. D. (2018) · Medicina · doi:10.3390/medicina54050088 · Cited by 75 · see citing works
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion
Sharma, N., Vacher, J., & Allison, J. P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819004116 · Cited by 75 · see citing works
Characteristics and clinical trial results of agonistic anti‑CD40 antibodies in the treatment of malignancies (Review)
Li, D., & Wang, W. (2020) · Oncology Letters · doi:10.3892/ol.2020.12037 · Cited by 73 · see citing works
Involvement of CCR6/CCL20/IL-17 Axis in NSCLC Disease Progression
Kirshberg, S., Izhar, U., Amir, G., Demma, J. A., Vernea, F., Beider, K., Shlomai, Z., Wald, H., Zamir, G. A., Shapira, O. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024856 · Cited by 71 · see citing works
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Luke, J. J., Barlési, F., Chung, K. Y., Tolcher, A. W., Kelly, K. L., Hollebecque, A., Tourneau, C. L., Subbiah, V., Tsai, F. Y.-C., Kao, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002015 · Cited by 68 · see citing works
CCL 2 as a potential therapeutic target for clear cell renal cell carcinoma
Arakaki, R., Yamasaki, T., Kanno, T., Shibasaki, N., Sakamoto, H., Utsunomiya, N., Sumiyoshi, T., Shibuya, S., Tsuruyama, T., Nakamura, E., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.886 · Cited by 63 · see citing works
Phase I dose‐escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer
Masuda, T., Noda, M., Kogawa, T., Kitagawa, D., Hayashi, N., Jomori, T., Nakanishi, Y., Nakayama, K. I., Ohno, S., & Mimori, K. (2020) · Cancer Science · doi:10.1111/cas.14306 · Cited by 63 · see citing works
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials
Oronsky, B. T., Paulmurugan, R., Foygel, K., Scicinski, J. J., Knox, S. J., Peehl, D. M., Zhao, H., Ning, S., Cabrales, P., Summers, T. A., et al. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1268600 · Cited by 62 · see citing works
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells
Khan, S., Weterings, J. J., Britten, C. M., de Jong, A. R., Graafland, D., Melief, C. J. M., van der Burg, S. H., MAREL, G. V. D., Overkleeft, H. S., Filippov, D. V., et al. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.10.006 · Cited by 61 · see citing works
The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages
Boyle, S. T., Faulkner, J. W., McColl, S. R., & Kochetkova, M. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0394-1 · Cited by 61 · see citing works
Maraviroc
Carter, N. J., & Keating, G. M. (2007) · Drugs · doi:10.2165/00003495-200767150-00010 · Cited by 60 · see citing works
Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
Sullivan, R. J., Hong, D. S., Tolcher, A. W., Patnaik, A., Shapiro, G. I., Chmielowski, B., Ribas, A., Brail, L. H., Roberts, J., Lee, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3013 · Cited by 59 · see citing works
Prognostic role of tumour-associated macrophages and macrophage scavenger receptor 1 in prostate cancer: a systematic review and meta-analysis
Cao, J., Liu, J., Xu, R., Zhu, X., Zhao, X., & Qian, B. (2017) · Oncotarget · doi:10.18632/oncotarget.18743 · Cited by 58 · see citing works
T-cell-independent Antitumor Effects of CD40 Ligation
Rakhmilevich, A. L., Alderson, K. L., & Sondel, P. M. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.698337 · Cited by 56 · see citing works
REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer
Oronsky, B. T., Reid, T. R., Larson, C., Caroen, S. Z., Quinn, M. G., Burbano, E., Varner, G., Thilagar, B., Brown, B., Coyle, A., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0317 · Cited by 56 · see citing works
Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway
Lv, J., Chen, F., Liu, C., Liu, P.-J., Feng, Z.-P., Li, J., Yang, Z.-X., Hou, F., & Deng, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117925 · Cited by 56 · see citing works
Trabectedin
Allavena, P., Germano, G., Belgiovine, C., D’Incalci, M., & Mantovani, A. (2013) · OncoImmunology · doi:10.4161/onci.24614 · Cited by 55 · see citing works
Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents
Zhang, X., Haney, K. M., Richardson, A. C., Wilson, E. N., Gewirtz, D. A., Ware, J. L., Zehner, Z. E., & Zhang, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.003 · Cited by 51 · see citing works
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present
Denny, W. A., & Flanagan, J. U. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1839414 · Cited by 51 · see citing works
Advances of CCR5 antagonists: From small molecules to macromolecules
Qi, B., Fang, Q., Liu, S., Hou, W., Li, J., Huang, Y., & Shi, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112819 · Cited by 50 · see citing works
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL
Bouwstra, R., He, Y. Z., de Boer, J., Kooistra, H., Cendrowicz, E., Fehrmann, R. S. N., Ammatuna, E., zu Eulenburg, C., Nijland, M., Huls, G. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0781 · Cited by 46 · see citing works
Self-citation
Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
Cassier, P. A., Treilleux, I., Bachelot, T., Ray-Coquard, I. L., Bendriss‐Vermare, N., Ménétrier‐Caux, C., Trédan, O., Goddard‐Léon, S., Pin, J., Mignotte, H., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-213 · Cited by 40 · see citing works
Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
Wang, S., Astsaturov, I. A., Bingham, C. A., McCarthy, K., von Mehren, M., Xu, W., Alpaugh, R. K., Tang, Y., Littlefield, B. A., Hawkins, L. D., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1090-7 · Cited by 39 · see citing works
Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107
CHE, L.-F., Shao, S.-F., & Wang, L. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2911 · Cited by 39 · see citing works
The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma
Zhou, Z., Li, Y., Kuang, M., Wang, X., Jia, Q., Cao, J., Hu, J., Wu, S., Wang, Z. P., & Xiao, J. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102598 · Cited by 38 · see citing works
Overexpression of CCL20 and its receptor CCR6 predicts poor clinical prognosis in human gliomas
Wang, L., Qin, H., Li, L., Zhang, Y., Tu, Y., Feng, F., Ji, P., Zhang, J., Li, G., Zhao, Z., et al. (2012) · Medical Oncology · doi:10.1007/s12032-012-0314-9 · Cited by 37 · see citing works
A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging
He, H., Tu, X., Zhang, J., Acheampong, D. O., Ding, L., Ma, Z., Ren, X., Luo, C., Chen, Z., Wang, T., et al. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.07.010 · Cited by 34 · see citing works
CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage
Eckstein, M., Epple, E., Jung, R., Weigelt, K., Lieb, V., Sikic, D., Stöhr, R., Geppert, C. I., Weyerer, V., Bertz, S., et al. (2020) · Cancers · doi:10.3390/cancers12051253 · Cited by 31 · see citing works
ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)
Tap, W. D. (2020) · Future Oncology · doi:10.2217/fon-2020-0307 · Cited by 31 · see citing works
Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment
Pilch, Z., Tonecka, K., Braniewska, A., Sas, Z., Skorzynski, M., Boon, L., Gołąb, J., Meyaard, L., & Rygiel, T. P. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0454 · Cited by 30 · see citing works
Self-citation
The CCR2/MCP-1 Chemokine Pathway and Lung Adenocarcinoma
Mittal, P., Wang, L., Akimova, T., Leach, C. A., Clemente, J. C., Sender, M., Chen, Y., Turunen, B. J., & Hancock, W. W. (2020) · Cancers · doi:10.3390/cancers12123723 · Cited by 30 · see citing works
Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
Haag, G. M., Halama, N., Springfeld, C., Grün, B., Apostolidis, L., Zschäbitz, S., Dietrich, M., Berger, A.-K., Weber, T. F., Zoernig, I., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3010 · Cited by 29 · see citing works
The saponin DT-13 inhibits gastric cancer cell migration through down-regulation of CCR5-CCL5 axis
Lin, S., Fan, W. Q., Sun, L., Li, F., Zhao, R., Zhang, L., Yu, B., & Yuan, S. (2014) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(14)60125-4 · Cited by 28 · see citing works
Influence of Costimulatory Molecules on Immune Response toLeishmania majorby Human Cells In Vitro
Brodskyn, C., DeKrey, G. K., & Titus, R. G. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.665-672.2001 · Cited by 27 · see citing works
Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
Dheilly, E., Majocchi, S., Moine, V., Didelot, G., Broyer, L., Calloud, S., Malinge, P., Chatel, L., Ferlin, W. G., Kosco‐Vilbois, M. H., et al. (2018) · Antibodies · doi:10.3390/antib7010003 · Cited by 26 · see citing works
Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
Zhang, Y., Wang, P., Wang, T., Fang, Y., Ding, Y., & Qian, Q. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02750-4 · Cited by 26 · see citing works
Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer
Schalper, K. A., Carvajal‐Hausdorf, D., McLaughlin, J. F., Velcheti, V., Chen, L., Sanmamed, M. F., Herbst, R. S., & Rimm, D. L. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p415 · Cited by 25 · see citing works
CtBP1 promotes tumour‐associated macrophage infiltration and progression in non–small‐cell lung cancer
Wang, Z., Zhao, Y., Xu, H., Liang, F., Zou, Q., Wang, C., Jiang, J., & Lin, F. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15751 · Cited by 24 · see citing works
TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1
Shih, C.-T., Shiau, C., Chen, Y., Chen, L.-J., Chao, T.-I., Wang, C., Huang, C., Hung, M., & Chen, K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.043 · Cited by 24 · see citing works
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
Oronsky, B. T., Carter, C. A., Caroen, S. Z., Scribner, C. L., Oronsky, A. L., & Reid, T. R. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1746172 · Cited by 22 · see citing works
Evaluation of CD24 and CD44 as cancer stem cell markers in squamous cell carcinoma and epithelial dysplasia of the oral cavity by q- RT-PCR
Saghravanian, N., Mirhashemi, M., Ghazi, N., Taghipour, A., & Mohajertehran, F. (2020) · Dental Research Journal · doi:10.4103/1735-3327.284727 · Cited by 22 · see citing works
The expression and significance of tumor associated macrophages and CXCR4 in non-small cell lung cancer.
Wei, Y., Wang, X., Shengjun, Y., Shaohui, Z., & Hongzhen, Z. (2018) · PubMed · Cited by 20 · see citing works
Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
Hindi, N., García, I. C., Sánchez-Camacho, A., Gutierrez, A. M., Peinado, J., Rincón, I., Benedetti, J., Sancho, P., Santos, P., Sánchez-Bustos, P., et al. (2020) · Cancers · doi:10.3390/cancers12123740 · Cited by 20 · see citing works
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer
Pignata, S., Scambia, G., Villanucci, A., Naglieri, E., Ibarbia, M. A., Brusa, F., Bourgeois, H. P., Sorio, R., Casado, A., Reichert, D. A., et al. (2020) · The Oncologist · doi:10.1002/onco.13630 · Cited by 20 · see citing works
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
Evers, M., ten Broeke, T., Jansen, J. H. M., Nederend, M., Hamdan, F., Reiding, K., Meyer, S., Moerer, P., Brinkman, I., Rösner, T., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1795505 · Cited by 19 · see citing works
Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).
Autio, K. A., Klebanoff, C. A., Schaer, D., Kauh, J. S. W., Slovin, S. F., Blinder, V. S., Comen, E. A., Danila, D. C., Hoffman, D., Kang, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2548 · Cited by 17 · see citing works
Efficacy of trabectedin for the treatment of liposarcoma
Zijoo, R., & von Mehren, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1229304 · Cited by 14 · see citing works
A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors.
Harb, W. A., Johnson, M. L., Goldman, J. W., Weise, A. M., Call, J., Dudek, A. Z., Gonzalez, R. C., Cowey, C. L., Eves, P. T., Gollerkeri, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps3110 · Cited by 14 · see citing works
Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results
Sanborn, R. E., Gabrail, N. Y., Bhardwaj, N., Gordon, M. S., O’Hara, M. H., Khalil, D. N., Hawthorne, T. R., Gedrich, R. W., Vitale, L. A., Rogalski, M., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-lb-194 · Cited by 10 · see citing works
Absence of CCR2 reduces spontaneous intestinal tumorigenesis in the ApcMin /+ mouse model
Jala, V. R., Bodduluri, S. R., Ghosh, S., Chheda, Z. S., Singh, R., Smith, M. E., Chilton, P. M., Fleming, C., Mathis, S., Sharma, R., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33477 · Cited by 10 · see citing works
Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer
Kikuchi, S., Noguchi, K., Wakai, K., Hamazaki, Y., Tozawa, K., Jomori, T., Sasako, M., & Miwa, H. (2019) · Anticancer Research · doi:10.21873/anticanres.13651 · Cited by 8 · see citing works
Abstract C087: Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including diffuse-type tenosynovial giant cell tumor
Taylor, M. H., Leong, S., Su, Y., Leary, C. B., Li, X., Kuida, K., Ruiz‐Soto, R., & Bauer, T. M. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-19-c087 · Cited by 8 · see citing works
Abstract CT233: Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients
Cristofanilli, M., Dolezal, M., Lalezari, J., Rui, H., Patterson, B. K., Tang, C., Adams, D. L., Zhang, Q., Kazempour, K., Pourhassan, N. Z., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-ct233 · Cited by 7 · see citing works
Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma
Sabado, R. L., Pavlick, A. C., Gnjatic, S., Cruz, C. M., Vengco, I., Hasan, F., Darvishian, F., Chiriboga, L. A., Holman, R. M., Escalon, J., et al. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-s1-p272 · Cited by 4 · see citing works
Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma
Matsuda, S., Tanaka, K., Kawano, M., Iwasaki, T., Itonaga, I., & Tsumura, H. (2020) · Medicine · doi:10.1097/md.0000000000018689 · Cited by 4 · see citing works

Flagged first, then by citations

11 of the 199 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

[61]Yue G.G.L. Chan B.C.L. Hon P.-M. Lee M.Y.H. Fung K.-P. Leung P.-C. NIH Public Access Bone 2010 23 1 7 10.1038/nature04186.VEGFR1-positive · DOI

Sorted by citations

Tumor-associated macrophages: an effective player of the tumor microenvironment
Basak, U., Sarkar, T., Mukherjee, S., Chakraborty, S., Dutta, A., Dutta, S., Nayak, D., Kaushik, S., Das, T., & Sa, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295257 · Cited by 346 · see citing works
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
Kundu, M., Butti, R., Panda, V. K., Malhotra, D., Das, S., Mitra, T., Kapse, P., Gosavi, S., & Kundu, G. C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01990-4 · Cited by 273 · see citing works
The role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 228 · see citing works
Roles of macrophages on ulcerative colitis and colitis-associated colorectal cancer
Zhang, M., Li, X., Zhang, Q., Yang, J., & Liu, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1103617 · Cited by 201 · see citing works
Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options
Sas, Z., Cendrowicz, E., Weinhäuser, I., & Rygiel, T. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073778 · Cited by 178 · see citing works
Self-citation
Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism
Ou, S., Wang, H., Tao, Y., Luo, K., Ye, J., Ran, S., Guan, Z., Wang, Y., Hu, H., & Huang, R. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1020583 · Cited by 135 · see citing works
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors
Hadiloo, K., Taremi, S., Heidari, M., & Esmaeilzadeh, A. (2023) · Biomarker Research · doi:10.1186/s40364-023-00537-x · Cited by 122 · see citing works
Bifidobacterium breve -derived indole-3-lactic acid ameliorates colitis-associated tumorigenesis by directing the differentiation of immature colonic macrophages
Li, Y., Li, Q., Yuan, R., Wang, Y., Guo, C., & Wang, L. (2024) · Theranostics · doi:10.7150/thno.92350 · Cited by 112 · see citing works
How Do ROS Induce NETosis? Oxidative DNA Damage, DNA Repair, and Chromatin Decondensation
Azzouz, D., & Palaniyar, N. (2024) · Biomolecules · doi:10.3390/biom14101307 · Cited by 108 · see citing works
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Datsi, A., & Sorg, R. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770390 · Cited by 102 · see citing works
T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems
Yang, Y., Yang, F., Huang, Z.-Q., Li, Y.-Y., Shi, H.-Y., Sun, Q., Ma, Y., Wang, Y., Zhang, Y., Yang, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199173 · Cited by 99 · see citing works
TAM family kinases as therapeutic targets at the interface of cancer and immunity
DeRyckere, D., Huelse, J. M., Earp, H. S., & Graham, D. K. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00813-7 · Cited by 98 · see citing works
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy
Peng, Y., Liang, S., Meng, Q., Liu, D., Ma, K., Zhou, M., Yun, K., Rao, L., & Wang, Z. (2024) · Advanced Materials · doi:10.1002/adma.202313188 · Cited by 91 · see citing works
The regulatory landscape of macrophage interferon signaling in inflammation
Siebeler, R., de Winther, M. P. J., & Hoeksema, M. A. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.04.022 · Cited by 91 · see citing works
Cytokines: Can Cancer Get the Message?
Morris, R. M., Mortimer, T. O., & O'Neill, K. L. (2022) · Cancers · doi:10.3390/cancers14092178 · Cited by 90 · see citing works
Extracellular matrix: unlocking new avenues in cancer treatment
Lee, J. J., Ng, K. Y., & Bakhtiar, A. (2025) · Biomarker Research · doi:10.1186/s40364-025-00757-3 · Cited by 76 · see citing works
Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies
Natu, J., & Nagaraju, G. P. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216382 · Cited by 73 · see citing works
The Role of Metabolic Plasticity of Tumor-Associated Macrophages in Shaping the Tumor Microenvironment Immunity
Hasan, M. N., Capuk, O., Patel, S. M., & Sun, D. (2022) · Cancers · doi:10.3390/cancers14143331 · Cited by 72 · see citing works
Beta-glucan: An overview in biological activities, derivatives, properties, modifications and current advancements in food, health and industrial applications
Edo, G. I., Ndudi, W., Makia, R. S., Ainyanbhor, I. E., Yousif, E. A., Gaaz, T. S., Zainulabdeen, K., Jikah, A. N., Opiti, R. A., Akpoghelie, P. O., et al. (2024) · Process Biochemistry · doi:10.1016/j.procbio.2024.09.011 · Cited by 71 · see citing works
Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis
Shah, S., & D’Souza, G. G. M. (2025) · Cells · doi:10.3390/cells14100732 · Cited by 66 · see citing works
“Thus, TAMs serve as both immunological suppressors and facilitators of malignant progression [70,71].”
Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs
Shao, S., Miao, H., & Ma, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295684 · Cited by 66 · see citing works
Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?
Elkoshi, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821598 · Cited by 61 · see citing works
Nanobodies in cell-mediated immunotherapy: On the road to fight cancer
Maali, A., Gholizadeh, M., Feghhi-Najafabadi, S., Noei, A., Seyed-Motahari, S. S., Mansoori, S., & Sharifzadeh, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1012841 · Cited by 62 · see citing works
The role of B cells in cancer development
Tan, R., Nie, M.-H., & Long, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958756 · Cited by 50 · see citing works
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Retecki, K., Seweryn, M., Graczyk‐Jarzynka, A., & Bajor, M. (2021) · Cancers · doi:10.3390/cancers13236012 · Cited by 54 · see citing works
Cholesterol: An important actor on the cancer immune scene
Halimi, H., & Farjadian, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1057546 · Cited by 56 · see citing works
Nanozymes with biomimetically designed properties for cancer treatment
Xu, K., Cui, Y., Guan, B., Qin, L., Feng, D., Abuduwayiti, A., Wu, Y., Li, H., Cheng, H., & Li, Z. (2024) · Nanoscale · doi:10.1039/d4nr00155a · Cited by 52 · see citing works
Obesity Programs Macrophages to Support Cancer Progression
Singh, A., Mayengbam, S. S., Yaduvanshi, H., Wani, M. R., & Bhat, M. K. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1257 · Cited by 46 · see citing works
Tumor associated macrophages in breast cancer progression: implications and clinical relevance
Stavrou, M., & Constantinidou, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1441820 · Cited by 46 · see citing works
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies
Gharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 53 · see citing works
Impact of immune cells on the hallmarks of cancer: A literature review
Costa, A. C., Santos, J., da Costa, R. M. G., & Medeiros, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103541 · Cited by 45 · see citing works
Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy
Guo, Y., Cen, K., Chen, Q., Dai, Y., Mai, Y., & Hong, K. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128390 · Cited by 45 · see citing works
Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers
Kotsifaki, A., Alevizopoulos, N., Dimopoulou, V., & Armakolas, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015332 · Cited by 46 · see citing works
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance
Dong, D., Xue, Y., Xu, J., Yu, N. H., Liu, Z., & Sun, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101125 · Cited by 47 · see citing works
Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy
Eptaminitaki, G. C., Wolff, N. S., Stellas, D., Sifakis, K., & Baritaki, S. (2021) · Cells · doi:10.3390/cells10123313 · Cited by 44 · see citing works
Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application
Li, A., & Fang, J. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230025 · Cited by 42 · see citing works
Progress of Nanomaterials in Photodynamic Therapy Against Tumor
Chen, L., Huang, J., Li, X., Huang, M., Zeng, S., Zheng, J., Peng, S., & Li, S. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.920162 · Cited by 39 · see citing works
A subpopulation of CD146+ macrophages enhances antitumor immunity by activating the NLRP3 inflammasome
Jing, L., An, Y., Cai, T., Xiang, J., Li, B., Guo, J., Ma, X., Wei, L., Tian, Y., Cheng, X., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01047-4 · Cited by 39 · see citing works
Tumor-derived extracellular vesicles regulate macrophage polarization: role and therapeutic perspectives
Wang, L., Wang, W., Hu, D., Liang, Y., Liu, Z., Zhong, T., & Wang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1346587 · Cited by 39 · see citing works
Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies
Caverzán, M. D., Beaugé, L., Oliveda, P. M., Cesca, B. A., Bühler, E. M., & Ibarra, L. E. (2023) · Brain Sciences · doi:10.3390/brainsci13040542 · Cited by 41 · see citing works
Melanoma Stem Cells Educate Neutrophils to Support Cancer Progression
Anselmi, M., Fontana, F., Marzagalli, M., Gagliano, N., Sommariva, M., & Limonta, P. (2022) · Cancers · doi:10.3390/cancers14143391 · Cited by 38 · see citing works
Enzyme‐Activatable Chemokine Conjugates for In Vivo Targeting of Tumor‐Associated Macrophages
Barth, N. D., van Dalen, F. J., Karmakar, U., Bertolini, M., Mendive‐Tapia, L., Kitamura, T., Verdoes, M., & Vendrell, M. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202207508 · Cited by 38 · see citing works
Nano‐bio interactions between 2D nanomaterials and mononuclear phagocyte system cells
Zhao, J., Chen, Z., Liu, S., Li, P., Yu, S., Ling, D., & Li, F. (2024) · BMEMat · doi:10.1002/bmm2.12066 · Cited by 37 · see citing works
Macrophages as a Potential Immunotherapeutic Target in Solid Cancers
Mishra, A., Banday, S., Bharadwaj, R., Ali, A., Rashid, R., Kulshreshtha, A., & Malonia, S. K. (2022) · Vaccines · doi:10.3390/vaccines11010055 · Cited by 37 · see citing works
Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs
Brady, R. V., & Thamm, D. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176807 · Cited by 35 · see citing works
Natural Killer Cell-Derived Extracellular Vesicles as a Promising Immunotherapeutic Strategy for Cancer: A Systematic Review
Chan, A. M. L., Cheah, J. M., Lokanathan, Y., Ng, M. H., & Law, J. X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044026 · Cited by 35 · see citing works
Sanguinarine Regulates Tumor-Associated Macrophages to Prevent Lung Cancer Angiogenesis Through the WNT/β-Catenin Pathway
Cui, Y., Luo, Y., Qian, Q., Tian, J., Fang, Z., Wang, X., Zeng, Y., Wu, J., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.732860 · Cited by 34 · see citing works
Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics
Zhang, Q., Zhang, N., Xiao, H., Wang, C., & He, L. (2023) · Cancers · doi:10.3390/cancers15235639 · Cited by 33 · see citing works
CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
Freile, J. Á., Avtenyuk, N. U., Corrales, M. G., Lourens, H. J., Huls, G. A., van Meerten, T., Cendrowicz, E., & Bremer, E. (2022) · Biomedicines · doi:10.3390/biomedicines10051175 · Cited by 32 · see citing works
Self-citation
Immune Cell‐Based Microrobots for Remote Magnetic Actuation, Antitumor Activity, and Medical Imaging
Dogan, N. O., Suadiye, E., Wrede, P., Lazović, J., Dayan, C. B., Soon, R. H., Aghakhani, A., Richter, G., & Sitti, M. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400711 · Cited by 31 · see citing works
Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication
Waldenmaier, M., Seibold, T., Seufferlein, T. T. W., & Eiseler, T. (2021) · Cancers · doi:10.3390/cancers13194844 · Cited by 31 · see citing works
Natural products targeting macrophages in tumor microenvironment are a source of potential antitumor agents
Liu, Q., Chen, Y., An, P., Rahman, K., Luan, X., & Zhang, H. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154612 · Cited by 30 · see citing works
Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment
Cao, J. H., Chow, L., & DOW, S. W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1116016 · Cited by 32 · see citing works
Uptake of Cyclodextrin Nanoparticles by Macrophages is Dependent on Particle Size and Receptor-Mediated Interactions
Soni, S. S., Kim, K. M., Sarkar, B., & Rodell, C. B. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00985 · Cited by 30 · see citing works
An NFAT1-C3a-C3aR Positive Feedback Loop in Tumor-Associated Macrophages Promotes a Glioma Stem Cell Malignant Phenotype
Zhang, Y., Song, Y., Wang, X., Shi, M., Lin, Y., Tao, D., & Han, S. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0418 · Cited by 30 · see citing works
Metabolism-inflammasome crosstalk shapes innate and adaptive immunity
Wu, J., Sun, X., & Jiang, P. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.04.006 · Cited by 32 · see citing works
Tumor‐associated macrophages: A sentinel of innate immune system in tumor microenvironment gone haywire
Malik, S., Sureka, N., Ahuja, S., Aden, D., Zaheer, S., & Zaheer, S. (2024) · Cell Biology International · doi:10.1002/cbin.12226 · Cited by 30 · see citing works
In situ production and precise release of bioactive GM-CSF and siRNA by engineered bacteria for macrophage reprogramming in cancer immunotherapy
Wang, Y., Fan, Y., Zhang, X., Liu, J., Sun, D., Liu, X., Bai, G., Liu, X., Wang, H., Zhang, Y., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123037 · Cited by 30 · see citing works
Targeting Metabolic Pathways of Myeloid Cells Improves Cancer Immunotherapy
Li, J., Bolyard, C. M., Xin, G., & Li, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.747863 · Cited by 29 · see citing works
A study on fractional tumor-immune interaction model related to lung cancer via generalized Laguerre polynomials
Hassani, H., Avazzadeh, Z., Agarwal, P., Mehrabi, S., Ebadi, M. J., Dahaghin, M. S., & Naraghirad, E. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-02006-3 · Cited by 29 · see citing works
SERS analysis of cancer cell-secreted purines reveals a unique paracrine crosstalk in MTAP-deficient tumors
Valera, P. S., Plou, J., Garcı́a, I., Astobiza, I., Viera, C., Aransay, A. M., Martín, J., Sasselli, I. R., Carracedo, A., & Liz‐Marzán, L. M. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2311674120 · Cited by 29 · see citing works
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity
Cendrowicz, E., Jacob, L., Greenwald, S., Tamir, A., Pecker, I., Tabakman, R., Ghantous, L., Tamir, L., Kahn, R., Avichzer, J., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02256-x · Cited by 27 · see citing works
Self-citation
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Yao, L., Wang, Q., & Ma, W. (2023) · Cancers · doi:10.3390/cancers15245857 · Cited by 27 · see citing works
Metabolic Hormones Modulate Macrophage Inflammatory Responses
Batty, M. J., Chabrier, G., Sheridan, A., & Gage, M. (2021) · Cancers · doi:10.3390/cancers13184661 · Cited by 27 · see citing works
Engineered Tumor–Immune Microenvironment On A Chip to Study T Cell–Macrophage Interaction in Breast Cancer Progression
Manoharan, T. J. M., Ravi, K., Suresh, A. P., Acharya, A. P., & Nikkhah, M. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303658 · Cited by 26 · see citing works
IL-6 facilitates cross-talk between epithelial cells and tumor- associated macrophages in Helicobacter pylori-linked gastric carcinogenesis
Yu, B., de Vos, D., Guo, X., Peng, S., Xie, W., Peppelenbosch, M. P., Fu, Y., & Fuhler, G. M. (2024) · Neoplasia · doi:10.1016/j.neo.2024.100981 · Cited by 26 · see citing works
FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer
Zhong, A., Chen, T., Xing, Y., Pan, X., & Shi, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.758648 · Cited by 26 · see citing works
Iron Oxide Nanoparticles for Visualization of Prostate Cancer in MRI
Kader, A., Kaufmann, J. O., Mangarova, D. B., Möckel, J., Brangsch, J., Adams, L. C., Zhao, J., Reimann, C., Saatz, J., Traub, H., et al. (2022) · Cancers · doi:10.3390/cancers14122909 · Cited by 25 · see citing works
In Situ Reprogramming of Immune Cells Using Synthetic Nanomaterials
Nie, S., Qin, Y., Ou, L., Chen, X. S., & Li, L. (2024) · Advanced Materials · doi:10.1002/adma.202310168 · Cited by 25 · see citing works
Recently Updated Role of Chitinase 3-like 1 on Various Cell Types as a Major Influencer of Chronic Inflammation
Mizoguchi, E., Sadanaga, T., Nanni, L., Wang, S., & Mizoguchi, A. (2024) · Cells · doi:10.3390/cells13080678 · Cited by 23 · see citing works
Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases
Khaled, M. L., Tarhini, A. A., Forsyth, P. A., Smalley, I., & Piña, Y. (2023) · Cancers · doi:10.3390/cancers15061884 · Cited by 25 · see citing works
GPER: An Estrogen Receptor Key in Metastasis and Tumoral Microenvironments
Tirado-Garibay, A. C., Falcón-Ruiz, E. A., Ochoa‐Zarzosa, A., & López-Meza, J. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914993 · Cited by 24 · see citing works
The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets
Lorestani, P., Dashti, M., Nejati, N., Habibi, M. A., Askari, M., Robat-Jazi, B., Ahmadpour, S., & Tavakolpour, S. (2024) · Discover Oncology · doi:10.1007/s12672-024-01256-x · Cited by 23 · see citing works
Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming
Thielman, N. R. J., Funes, V., Davuluri, S., Ibanez, H. E., Sun, W., Fu, J. L., Li, K., Muth, S., Pan, X., Fujiwara, K., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp0684 · Cited by 23 · see citing works
Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment
Zhang, G.-H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975762 · Cited by 22 · see citing works
The dichotomic role of single cytokines: Fine-tuning immune responses
Silva, R. C. M. C., Travassos, L. H., & Dutra, F. F. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156408 · Cited by 25 · see citing works
Glioma-associated macrophages: unraveling their dual role in the microenvironment and therapeutic implications
Wang, J., Li, S., Lan, Y., Liu, X., & Li, W. (2024) · Current Medicine · doi:10.1007/s44194-024-00031-y · Cited by 23 · see citing works
Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance
Monteleone, G., Franzè, E., Maresca, C., Colella, M., Pacifico, T., & Stolfi, C. (2023) · Cancers · doi:10.3390/cancers15030971 · Cited by 22 · see citing works
Kaempferia parviflora Extracellular Vesicle Loaded with Clarithromycin for the Treatment of Helicobacter pylori Infection
Nemidkanam, V., Banlunara, W., & Chaichanawongsaroj, N. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s444686 · Cited by 21 · see citing works
Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy
Nicolini, A., Ferrari, P., & Carpi, A. (2022) · Biomedicines · doi:10.3390/biomedicines10102511 · Cited by 20 · see citing works
Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials
Jiang, M., Fiering, S., & Shao, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1153066 · Cited by 22 · see citing works
Influence of Extracellular Vesicles on Lung Stromal Cells during Breast Cancer Metastasis
Patel, U., Susman, D., & Allan, A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411801 · Cited by 20 · see citing works
Tumor-Associated Macrophages Affect the Tumor Microenvironment and Radioresistance via the Upregulation of CXCL6/CXCR2 in Hepatocellular Carcinoma
Lee, H., Tsai, Y.-C., Pikatan, N. W., Yeh, C., Yadav, V. K., Chen, M., & Tsai, J. (2023) · Biomedicines · doi:10.3390/biomedicines11072081 · Cited by 20 · see citing works
The role of immune cells and immune related genes in the tumor microenvironment of papillary thyroid cancer and their significance for immunotherapy
Li, X., Jian, J., Zhang, A., Xiang, J., Huang, J., & Chen, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-69187-9 · Cited by 20 · see citing works
The tumor microenvironment and dendritic cells: Developers of pioneering strategies in colorectal cancer immunotherapy?
Ghorbaninezhad, F., Nour, M. A., Farzam, O. R., Saeedi, H., Vanan, A. G., Bakhshivand, M., Jafarlou, M., Hatami‐Sadr, A., & Baradaran, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189281 · Cited by 23 · see citing works
Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications
Banerjee, A., Narasimhulu, C. A., & Singla, D. K. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00378.2023 · Cited by 20 · see citing works
Bone Marrow Niches and Tumour Cells: Lights and Shadows of a Mutual Relationship
Granata, V., Crisafulli, L., Nastasi, C., Ficara, F., & Sobacchi, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884024 · Cited by 19 · see citing works
Potential PET tracers for imaging of tumor-associated macrophages
Fernandes, B., Feltes, P. K., Luft, C., Nazario, L. R., Jeckel, C. M. M., Antunes, I. F., Elsinga, P. H., & de Vries, E. F. J. (2022) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-022-00163-2 · Cited by 19 · see citing works
Development of siRNA and Budesonide Dual‐Loaded Hybrid Lipid–Polymer Nanoparticles by Microfluidics Technology as a Platform for Dual Drug Delivery to Macrophages: An In Vitro Mechanistic Study
Cérda, S. L., Fontana, F., Wang, S., Correia, A., Molinaro, G., Tello, R. P., Hirvonen, J. J., Celia, C., Barreto, G., & Santos, H. A. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300048 · Cited by 19 · see citing works
Macrophage infiltration in 3D cancer spheroids to recapitulate the TME and unveil interactions within cancer cells and macrophages to modulate chemotherapeutic drug efficacy
Singh, K., & Gautam, P. K. (2023) · BMC Cancer · doi:10.1186/s12885-023-11674-9 · Cited by 19 · see citing works
Defining and targeting macrophage heterogeneity in the mammary gland and breast cancer
Elfstrum, A. K., Bapat, A. S., & Schwertfeger, K. L. (2024) · Cancer Medicine · doi:10.1002/cam4.7053 · Cited by 21 · see citing works
Enhanced stem cell-mediated therapeutic immune modulation with zinc oxide nanoparticles in liver regenerative therapy
Park, N., Kim, K. S., Lee, S.-H., Choi, J. H., & Na, K. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123232 · Cited by 18 · see citing works
The role of SPP1 + TAMs in cancer: Impact on patient prognosis and future therapeutic targets
Li, X., Lian, J., & Lu, H. (2025) · International Journal of Cancer · doi:10.1002/ijc.70018 · Cited by 18 · see citing works
Tumor-educated cells in tumor microenvironment: Key drivers of immunotherapy resistance
Zou, J. P., Wang, S., Zhang, Y., Tian, W., Mai, G., Xu, Y., Xiao, W., Graves, E. E., & Wu, F. (2025) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2025.03.12 · Cited by 20 · see citing works
Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer
Polten, R., Kutle, I., Hachenberg, J., Klapdor, R., Morgan, M. A., & Schambach, A. (2022) · Cancers · doi:10.3390/cancers15010263 · Cited by 18 · see citing works
Dendritic cell vaccine of gliomas: challenges from bench to bed
Zheng, Y., Ma, X., Feng, S., Zhu, H., Chen, X., Yu, X., Shu, K., & Zhang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259562 · Cited by 19 · see citing works
Green Nanotechnology of Yucca filamentosa- Phytochemicals-Functionalized Gold Nanoparticles—Antitumor Efficacy Against Prostate and Breast Cancers
Thipe, V. C., Jatar, A., Karikachery, A. R., Katti, K. K., & Katti, K. V. (2023) · Nanotechnology Science and Applications · doi:10.2147/nsa.s437812 · Cited by 18 · see citing works
Breast Cancer Immune Landscape: Interplay Between Systemic and Local Immunity
Gerashchenko, T. S., Frolova, A. A., Patysheva, M. R., Fedorov, A. A., Stakheyeva, M. N., Denisov, E. V., & Чердынцева, Н. В. (2024) · Advanced Biology · doi:10.1002/adbi.202400140 · Cited by 18 · see citing works
The Physiological and Therapeutic Role of CD47 in Macrophage Function and Cancer
Bess, S. N., Igoe, M. J., & Muldoon, T. J. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2415409 · Cited by 17 · see citing works
Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response
Naei, V. Y., Tubelleza, R., Monkman, J. H., Sadeghirad, H., Donovan, M. L., Blick, T., Wicher, A. Z., Bodbin, S. E., Viratham, A., Stad, R. K., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06186-y · Cited by 17 · see citing works

Macrophage targeting in cancer
Lopez‐Yrigoyen, M., Cassetta, L., & Pollard, J. W. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14377 · Cited by 220 · see citing works
Tumor-Associated Macrophages: A Potential Target for Cancer Therapy
Tan, Y., Wang, M., Zhang, Y., Ge, S., Zhong, F., Xia, G., & Sun, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693517 · Cited by 134 · see citing works
Harnessing Macrophages in Cancer Therapy: from Immune Modulators to Therapeutic Targets
Tan, H., Cai, M., Wang, J., Yu, T., Xia, H., Zhao, H., & Zhang, X. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.106275 · Cited by 12 · see citing works
Tumor-Associated Macrophages as Target for Antitumor Therapy
Sawa-Wejksza, K., & Kandefer‐Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0480-8 · Cited by 199 · see citing works
Tumor-Associated Macrophages: Therapeutic Targets of Cancer
Li, Y., Zhang, X., Zeng, X. L., Wang, S., & Wang, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_13 · Cited by 1 · see citing works

Authors: Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P.
Affiliations: University Medical Center Groningen (NL)
Medical University of Warsaw (PL)
Corresponding author: Rygiel, Tomasz P.
ORCID: Cendrowicz, Ewa
Sas, Zuzanna
Bremer, Edwin
Rygiel, Tomasz P.
Venue: Cancers
Publisher: MDPI AG
Published: 2021-04-18
Volume: 13
Issue: 8
Pages: 1946
ISSN: 2072-6694 (ISSN-L)
DOI: 10.3390/cancers13081946
PMC: PMC8073377
OpenAlex: W3156547118
Cited by: 332
References: 199
Citations by year: 2026: 33 · 2025: 68 · 2024: 106 · 2023: 72 · 2022: 42 · 2021: 11
FWCI: 5.91
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cancers (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
Funders: Fundacja na rzecz Nauki Polskiej (TEAM TECH/2016-1/8)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Health Sciences › Medicine › Psychiatry and Mental health › Cancer, Stress, Anesthesia, and Immune Response
Keywords: tumor-associated macrophages, tumor microenvironment, TAM depletion, TAM reprogramming, tumor immunosuppression, neoangiogenesis, metastasis, antitumor immunity, T cell recruitment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Role of Macrophages in Cancer Development and Therapy

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks